Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer: Multicentre, Open-label,Phase 1B Safety Study
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Donafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
Most Recent Events
- 04 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 07 Jul 2015 New trial record